- Home
- REBN vs SABS Comparison
REBN vs SABS Comparison
Compare REBN & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- SABS
- Stock Information
- Founded
- REBN 2015
- SABS 2014
- Country
- REBN United States
- SABS United States
- Employees
- REBN N/A
- SABS N/A
- Industry
- REBN Restaurants
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- SABS Health Care
- Exchange
- REBN Nasdaq
- SABS Nasdaq
- Market Cap
- REBN 13.5M
- SABS 15.8M
- IPO Year
- REBN 2022
- SABS N/A
- Fundamental
- Price
- REBN $2.51
- SABS $1.78
- Analyst Decision
- REBN
- SABS Strong Buy
- Analyst Count
- REBN 0
- SABS 5
- Target Price
- REBN N/A
- SABS $11.40
- AVG Volume (30 Days)
- REBN 86.8K
- SABS 34.2K
- Earning Date
- REBN 03-31-2025
- SABS 05-19-2025
- Dividend Yield
- REBN N/A
- SABS N/A
- EPS Growth
- REBN N/A
- SABS N/A
- EPS
- REBN N/A
- SABS N/A
- Revenue
- REBN $5,928,533.00
- SABS $1,322,410.00
- Revenue This Year
- REBN $335.98
- SABS N/A
- Revenue Next Year
- REBN N/A
- SABS $50.00
- P/E Ratio
- REBN N/A
- SABS N/A
- Revenue Growth
- REBN 7.63
- SABS N/A
- 52 Week Low
- REBN $1.03
- SABS $1.00
- 52 Week High
- REBN $8.80
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- REBN 36.61
- SABS 58.36
- Support Level
- REBN $2.41
- SABS $1.53
- Resistance Level
- REBN $2.68
- SABS $1.85
- Average True Range (ATR)
- REBN 0.22
- SABS 0.15
- MACD
- REBN 0.02
- SABS 0.02
- Stochastic Oscillator
- REBN 16.88
- SABS 73.68
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.